Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 148 No. 3334 (2018)

Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: results of the Swiss Pituitary Registry (SwissPit)

  • Julia Kempf
  • Alexander Schmitz
  • Aline Meier
  • Neele Delfs
  • Beat Mueller
  • Javier Fandino
  • Philipp Schuetz
  • Sven Berkmann
DOI
https://doi.org/10.4414/smw.2018.14653
Cite this as:
Swiss Med Wkly. 2018;148:w14653
Published
22.08.2018

Summary

AIMS OF THE STUDY

Acromegaly due to a growth hormone-secreting pituitary adenoma is a rare disease with high morbidity if not treated adequately. Using data of the Swiss Pituitary Registry (SwissPit), we studied initial presentation and predictors for adverse clinical outcomes in acromegalic patients treated during the last 10 years in our institution.

METHODS

We evaluated 21 patients from the SwissPit registry with a final diagnosis of acromegaly confirmed by laboratory results (insulin-like growth factor-1 [IGF-1] and growth hormone suppression tests) and magnetic resonance imaging. Our main endpoint was clinical cure defined as complete remission, remission with need for medical treatment and uncontrolled disease defined by non-normalisation of IGF-1 and growth hormone levels.

RESULTS

The most prevalent clinical symptoms at presentation were acral enlargement (81%), headache (29%), macroglossia (29%) and visual field defects (19%). Arterial hypertension was present in 67%, carpal tunnel syndrome in 38% and diabetes in 24%. A total of 19 of the 21 patients underwent initial surgical treatment. Eight patients had complete remission and 13 patients had active disease, with 7 having remission with need for medical treatment and 6 uncontrolled disease. Larger initial adenoma size (odds ratio [OR] 12.0, 95% confidence interval [CI] 1.02–141.3; p = 0.048) and high post-operative IGF-1 levels (OR 4.5, 95% CI 1.1–19.2; p = 0.040) were predictors for non-full remission and uncontrolled disease, respectively.

CONCLUSION

This small, observational registry study showed a relevant success rate of initial pituitary surgery in patients with confirmed acromegaly. Initial tumour size and postoperative IGF-1 levels help to risk stratify patients regarding expected outcomes. In the case of disease persistence, a multimodal approach using drug and radiotherapy is mandatory.

References

  1. Buchfelder M, Schlaffer SM. The surgical treatment of acromegaly. Pituitary. 2017;20(1):76–83. doi:.https://doi.org/10.1007/s11102-016-0765-7
  2. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9. doi:.https://doi.org/10.1007/s11102-016-0754-x
  3. Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al.; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51. doi:.https://doi.org/10.1210/jc.2014-2700
  4. Bonadonna S, Doga M, Gola M, Mazziotti G, Giustina A. Diagnosis and treatment of acromegaly and its complications: consensus guidelines. J Endocrinol Invest. 2005;28(11, Suppl International):43–7.
  5. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22–32. doi:.https://doi.org/10.1007/s11102-016-0772-8
  6. Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM, et al.; Participants of the German Acromegaly Register. Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin Endocrinol (Oxf). 2009;71(3):400–5. doi:.https://doi.org/10.1111/j.1365-2265.2009.03547.x
  7. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al.; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–8. doi:.https://doi.org/10.1210/jc.2009-2670
  8. Almeida JP, Ruiz-Treviño AS, Liang B, Omay SB, Shetty SR, Chen YN, et al. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature. J Neurosurg. 2017;1:1–13. doi:.https://doi.org/10.3171/2017.2.JNS162673
  9. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33(4):610–7, discussion 617–8.
  10. Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 1969;16(CN_suppl_1):185–217. doi:.https://doi.org/10.1093/neurosurgery/16.CN_suppl_1.185
  11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9. doi:.https://doi.org/10.1016/j.ijsu.2014.07.013
  12. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14(3):284–94. doi:.https://doi.org/10.1007/s11102-011-0310-7
  13. Briceno V, Zaidi HA, Doucette JA, Onomichi KB, Alreshidi A, Mekary RA, et al. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res. 2017;39(5):387–98. doi:.https://doi.org/10.1080/01616412.2017.1296653
  14. Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20(1):46–62. doi:.https://doi.org/10.1007/s11102-017-0797-7